Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: 4toSchool, Go-Gold, GoldenMind, Aces-DeucesMM, StemCellJunkie
Search This Board: 
Last Post: 3/22/2018 7:46:27 PM - Followers: 801 - Board type: Free - Posts Today: 202


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks

SUNRISE, Fla.Jan. 8, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement.  Details of the procedure and the results are featured in the January issue of Men's Healthon newsstands now. Link here!!! ----->>>>

Ben Greenfield posted (Jan 16th, 2018) video at US Stem Cell clinic in Florida

Expecting Ben Greenfield's article to be found here once written any day now...

Press Releases:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: American Premium Water Corp. (HIPH) Distribution in GNC - General Nutrition Center 06:52 AM
USRM News: Quarterly Report (10-q) 11/07/2017 04:04:52 PM
News News Alert: American Premium Water Corp. (HIPH) Distribution in GNC - General Nutrition Center 03/22/2018 06:52:42 AM
PlusOneCoin Top Posts
#89993   USRM Demonstrates 99% Reduction in Severity of Psoriasis midas716 03/21/18 10:35:16 AM
#89896   *NEWS* USRM Chief Science Officer to Present BillyBahama 03/20/18 08:47:49 AM
#89891   Smart pill, other Florida innovations could aid opioid MyzStreet 03/20/18 07:53:01 AM
#89993  Sticky Note USRM Demonstrates 99% Reduction in Severity of Psoriasis midas716 03/21/18 10:35:16 AM
#89744  Sticky Note Insider Financial US Stem Cell Inc (OTCMKTS:USRM) Still docprep 03/16/18 04:38:49 AM
#88723  Sticky Note I do not know what this will result a1tellem 02/28/18 08:03:26 PM
#88509  Sticky Note CEO Blog : Fe 4toSchool 02/24/18 05:16:16 PM
#85293  Sticky Note $USRM in 1 year has ~X3 Profits,~X2 revenues,~X4 GoldenMind 12/04/17 04:27:33 PM
#79439  Sticky Note BOARD WARNING: Please Read IH Geek [Dave] 09/14/17 12:53:48 PM
#90400   Trust me I know. I watch time and midas716 03/22/18 07:09:48 PM
#90399   SO SICKENING!!!!!! GOOD GOD PLEASE SEND THESE MMs Tim808 03/22/18 07:09:24 PM
#90398   Agreed, cant wait, it is coming. Glta kennyt 335 03/22/18 04:42:54 PM
#90397   Nice. 100mil valuation coming here Afterhoursearnings3 03/22/18 04:42:13 PM
#90396   No sir l do not, got all l need... kennyt 335 03/22/18 04:40:29 PM
#90395   Shaving an 8th off after jumping by a Afterhoursearnings3 03/22/18 04:33:51 PM
#90394   Wrong hemisphere! today kennyt 335 03/22/18 04:26:15 PM
#90393   Anyone who has been here a while knows Afterhoursearnings3 03/22/18 04:25:17 PM
#90392   Off by 7% kennyt 335 03/22/18 04:24:43 PM
#90391   Noticed that as well. Odd. USRM is still Afterhoursearnings3 03/22/18 04:23:45 PM
#90390   Someone has not gotten their ideal # of Afterhoursearnings3 03/22/18 04:20:21 PM
#90389   Several trades of 123. That must be sofakingwetoddid 03/22/18 04:20:13 PM
#90388   Exactly. All those trades happened in the span docprep 03/22/18 04:16:53 PM
#90387   Closed above 7..I am happy as a clam. Afterhoursearnings3 03/22/18 04:16:10 PM
#90386   lol there is 1 gap at .0675...not gonna Afterhoursearnings3 03/22/18 04:13:44 PM
#90385   trade war has nothing to do with this StemCellJunkie 03/22/18 04:09:46 PM
#90384   I'll be back in tomorrow when it drops Joeymc77 03/22/18 04:01:48 PM
#90383   All of my stocks just went red. Dow midas716 03/22/18 03:56:31 PM
#90382   Volume today MikeP21 03/22/18 03:53:59 PM
#90381   Wow! Buy signal was showing itself and I outnabout 03/22/18 03:49:53 PM
#90380   A slot shares in stronger hands. Candystore 03/22/18 03:43:22 PM
#90379   +35% yesterday, down 5% today. I'll take ozzy2704 03/22/18 03:42:13 PM
#90378   Very close to PSAR on the 10 day midas716 03/22/18 03:33:06 PM
#90377   HIT IT ! kaos2k 03/22/18 03:31:53 PM
#90375   L.A. Times SHREDS Comella and USRM "ED" supposed "treatment"... Hornet Driver 03/22/18 03:19:45 PM
#90374   tdog THANKS learn/ing 03/22/18 03:10:22 PM
#90373   Old article. April 2017 sum guy 03/22/18 03:09:07 PM
#90372   Article: USCC/Comella, "MORE EGREGIOUS THAN IMAGINED"… Hornet Driver 03/22/18 03:06:19 PM
#90371   Some times I have been thinking if this Bigdollars1 03/22/18 03:05:02 PM
#90370   It's prepping for a launch North. L2 has $$IsEverything$$83 03/22/18 03:01:32 PM
#90369   Any way to see the invisible and bottomless asks? kaos2k 03/22/18 02:55:35 PM
#90367   Might be a good time to get in? Jimscall 03/22/18 02:51:47 PM
#90366   Ok, we can trash the Mandalay Bay too. kaos2k 03/22/18 02:51:33 PM
#90364   I loaded .074s. I’m confident the filings will JPL1868 03/22/18 02:49:07 PM
#90363   FDA STARTS 2018 w/ NEW "SVF" WARNING LETTER... Hornet Driver 03/22/18 02:46:03 PM
#90362   Let's see what power hour brings us today. Candystore 03/22/18 02:37:19 PM
#90361   REAL-TIME LEVEL 2 QUOTE StemCellJunkie 03/22/18 02:29:56 PM
#90360   Should be 90 days brings us to April Stubbornseller 03/22/18 02:21:03 PM
#90359   If so then yes! Bearpaw1977 03/22/18 02:19:39 PM
#90358   Got it thanks bro! Deal McMogulson 03/22/18 02:11:55 PM
#90357   Within 90 days of end of fiscal year. Afterhoursearnings3 03/22/18 02:11:28 PM
#90356   For those of you buying at these levels, kennyt 335 03/22/18 02:11:10 PM
#90355   I didn’t ask him for a specific date. Deal McMogulson 03/22/18 02:10:30 PM
#90354   Lol why would you even ask? Lets not Afterhoursearnings3 03/22/18 02:08:32 PM
#90351   Anyone know the actual date the Q is Deal McMogulson 03/22/18 01:59:38 PM
#90350   Miami, in less than 6 months at $5 seamop 03/22/18 01:58:57 PM
#90349   As soon as volume dies, MMs walk down Lonewolf1 03/22/18 01:56:58 PM
#90348   What's the date and where are we meeting? kaos2k 03/22/18 01:53:51 PM
#90347   This will be in paper land soon enough. sdave2002 03/22/18 01:49:19 PM
#90346   I'm loaded and biased. Candystore 03/22/18 01:42:05 PM